<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397199</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP052</org_study_id>
    <nct_id>NCT03397199</nct_id>
  </id_info>
  <brief_title>Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the&#xD;
      Therapy of Advanced Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is a common clinical gastrointestinal cancer. In addition to the early&#xD;
      diagnosis of some patients, approximately 50% of patients have had distant metastases at the&#xD;
      time of diagnosis. For patients with advanced colorectal cancer, systemic chemotherapy is the&#xD;
      main treatment. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the&#xD;
      therapy of these patients. We designed the study to explore the possibility of apatinib for&#xD;
      Advanced Colorectal Cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR&#xD;
+ PR + SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib + S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib + S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib + S-1</intervention_name>
    <description>Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA &lt;1.4, 60mg bid BSA&gt;1.4），bid,from day1-day 14.</description>
    <arm_group_label>Apatinib + S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form prior to patient entry.&#xD;
&#xD;
          2. Histologically or cytologically diagnosed as metastatic colon or rectal adenocarcinoma&#xD;
             patients.&#xD;
&#xD;
          3. The second-line standard regimen failed (disease progression) and the chemotherapy&#xD;
             regimen included fluorouracil (5-FU / capecitabine / tioguanide), oxaliplatin and&#xD;
             irinotecan from the last chemotherapy&gt; 14 days.&#xD;
&#xD;
          4. ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.&#xD;
&#xD;
          6. Life expectancy of more than 3 months.&#xD;
&#xD;
          7. According to the solid tumor efficacy evaluation criteria RECISTv1.1 standards, at&#xD;
             least one measurable lesions. If the previous treatment of local treatment&#xD;
             (radiotherapy, radiofrequency, intervention, etc.) is the only focus of lesions, the&#xD;
             request must have a clear imaging progress.&#xD;
&#xD;
          8. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥1.5×109/L, PLT ≥&#xD;
             100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST≤ 2.5×ULN (or ≤ 5×ULN in patients&#xD;
             with liver metastases), Serum Cr≤ 1.5×ULN, Cr clearance ≥ 60 mL/min.&#xD;
&#xD;
          9. Female subjects of child-bearing potential must agree to use contraceptive measures&#xD;
             starting 1 week before the administration of the first dose of apatinib until 6 months&#xD;
             after discontinuing study drug. Male subjects must agree to use contraceptive measures&#xD;
             during the study and 6 months after last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite&#xD;
             optimal medical therapy).&#xD;
&#xD;
          2. Poor glycemic control in diabetes.&#xD;
&#xD;
          3. Acute cerebral infarction, or recovery period &lt;2 months.&#xD;
&#xD;
          4. A variety of factors that affect oral absorption (such as inability to swallow,&#xD;
             nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).&#xD;
&#xD;
          5. Patients with gastrointestinal bleeding risk may not be included, including the&#xD;
             following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of&#xD;
             melena and vomiting within 3 months；Fecal occult blood (+) is not an exclusion&#xD;
             criterion.&#xD;
&#xD;
          6. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN + 4s or APTT&gt; 1.5 ULN), with bleeding&#xD;
             tendency or ongoing thrombolysis or anti-blood coagulation treatment.&#xD;
&#xD;
          7. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies that&#xD;
             the 24-h urine protein quantitation ≥ 1.0 g.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. Cytotoxic drug treatment, radiotherapy within 2 weeks after treatment; had taken two&#xD;
             or more oral targeted drugs.&#xD;
&#xD;
         10. Other malignant tumors, cutaneous basal cell carcinoma, and cervical cancer in situ in&#xD;
             the past 5 years.&#xD;
&#xD;
         11. The investigators believe there is any condition that may harm the subject or result&#xD;
             in the subject's inability to meet or perform the research requirements&#xD;
&#xD;
         12. Severe liver and kidney dysfunction (grade 4) patients should be excluded.&#xD;
&#xD;
         13. Any allergy to apatinib should be excluded.&#xD;
&#xD;
         14. Persons with a history of substance abuse who can not be abdicated or have mental&#xD;
             disorders.&#xD;
&#xD;
         15. Previously used regurgitine is not an exclusion criterion.&#xD;
&#xD;
         16. According to the judgment of the researcher, there is a concomitant disease that&#xD;
             seriously endangers the patient's safety or affects the patient in completing the&#xD;
             study.&#xD;
&#xD;
         17. Patients who underwent surgery within 4 weeks prior to the start of treatment or who&#xD;
             had major trauma or fractures. Or there is an unhealed wound before treatment.&#xD;
&#xD;
         18. Patients with severe heart disease such as grade III or above (NYHA standard)&#xD;
             congestive heart failure, grade III or above (CCS standard) angina, or a history of&#xD;
             myocardial infarction within 6 months prior to the start of treatment, or patients&#xD;
             requiring medication Arrhythmia.&#xD;
&#xD;
         19. A brain metastasis, meningeal transfer.&#xD;
&#xD;
         20. Active HBV infection and refusal of regular antiviral treatment.&#xD;
&#xD;
         21. Active tuberculosis patients.&#xD;
&#xD;
         22. Participate in any drug or medical device clinical trial within 1 month before the&#xD;
             test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suxia Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ning Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

